Paratek Pharmaceuticals, Inc. announced that the company's independent directors of the board have appointed Jeffrey Stein, PhD as its first Lead Independent Director, effective December 8, 2022. Dr. Stein was selected unanimously by the independent directors of the Board, in recognition of his extensive leadership experience, in-depth knowledge of the company and the business of the anti-infective industry, strong financial and operational track record, and demonstrated independent judgment, integrity and commitment to the role. Having served as a director of the company since its emergence as a public company in 2014, Dr. Stein has broad experience, including as current President, CEO and Director of Cidara Therapeutics, Inc. since 2014, and previously CEO of Truis Therapeutics, Inc. from 2007, until its acquisition by Cubist Pharmaceuticals, Inc. in 2013.

As lead independent director, Dr. Stein will assume all the duties and responsibilities of the position, including presiding over executive sessions of independent directors, being an externally facing independent director, and coordinating with Michael F. Bigham, Executive Chairman in overall governance and Board matters. Dr. Stein will continue to serve as Chair of the Board's Compensation Committee and member of the Audit Committee.